Some with early relapsing MS felt unsure about treatment
By MS Buddy ·
Summarized from Neurology and therapy, Nov 2026 · PubMed · DOI. AI-generated summary. Not medical advice.
Observational study · 145 people in Spain with early relapsing MS receiving treatment
Research by Inés González-Suárez, Jorge Maurino and 18 colleagues at Hospital Universitario Álvaro Cunqueiro, Hospital Rafael Méndez and 12 other institutions in Spain.
How do people with early relapsing MS feel about choosing treatment?
Key Takeaway
About one in four people with early relapsing MS felt uncertain about their treatment decision.

What They Found
Researchers studied how people with early relapsing MS felt about choosing an MS treatment with their care team. Most rated the decision process favorably, but only about one in four reported high satisfaction. About 27% reported serious uncertainty about their treatment decision. Greater uncertainty about MS, a more threatening view of the illness, and a stronger impact from fatigue were linked to decision uncertainty. Men and people who had more relapses were less likely to report high satisfaction with the decision process.
Who Should Care and Why
The study included adults in Spain diagnosed with relapsing MS within the past three years. All were receiving an MS treatment. The findings describe their experience of making treatment choices with their care team. They show that a favorable overall rating did not always mean high satisfaction. They also show that feelings about living with MS were linked to uncertainty about treatment decisions.
Important Considerations
You should know this study surveyed 145 people at 16 clinics in Spain at one point in time. You cannot tell from this study whether fatigue or views about MS caused decision uncertainty. It did not compare treatments or test a way to improve decisions.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Neurology and therapy by et al.. Reproduced from the PubMed record.
Selecting a disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS) is a preference-sensitive decision where shared decision-making (SDM) is essential. This study aimed to evaluate the perceived quality of the SDM process and identify independent determinants of decisional conflict among patients with early-stage RRMS. This non-interventional, cross-sectional, multicenter study across 16 Spanish neuroimmunology clinics evaluated adults with early RRMS (≤ 3 years disease duration from diagnosis) receiving DMTs. SDM process quality and decisional conflict were assessed using the AGA-25 questionnaire and the SURE tests, respectively. Multivariable logistic regression models were constructed to identify independent determinants of high process satisfaction and decisional conflict. The evaluable population comprised 145 patients (mean age 37.6 years, 69.0% female). Participants evaluated the SDM process favorably (mean total AGA-25 score 67.1 [SD 9.1]). High process satisfaction was reported by 26.2% of patients (n = 38). In multivariable analysis, male sex and a higher total number of relapses since disease onset were associated with significantly lower odds of high process satisfaction, whereas higher decisional certainty was an independent positive determinant. Clinically significant decisional conflict was present in 27.1% of participants (n = 36). In the multivariable model, greater illness-related uncertainty, a more threatening illness perception, and higher fatigue impact independently increased the likelihood of decisional conflict. Although patients with early-stage RRMS generally report a favorable overall perception of collaborative treatment selection, high process satisfaction is attained by only approximately one-quarter of patients. Furthermore, clinically significant decisional conflict affects over 27% of individuals early in their disease course. This decisional distress is driven predominantly by the subjective emotional and perceptual burden of living with MS, rather than objective physical disability.
Categories
Explore more research
Related MS research

11/19/2026
A review of 50 studies found wide differences in MS rates across the Americas. MS became more common
Read More
11/20/2026
A study of online MS medication discussions found two main styles: sharing personal experiences and
Read More
11/18/2026
A review finds limited direct evidence that diet, exercise, or gut microbes affect MS through the bo
Read More
11/19/2026
Interviews with 17 people newly diagnosed with relapsing-remitting MS explored fear, doubt, and unce
Read More
11/18/2026
This review explores how pregnancy may affect MS and other diseases involving immune attacks on the
Read More
11/15/2026
A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
